» Articles » PMID: 32439204

Platelet-leukocyte Interplay During Vascular Disease

Overview
Journal Atherosclerosis
Publisher Elsevier
Date 2020 May 23
PMID 32439204
Citations 64
Authors
Affiliations
Soon will be listed here.
Abstract

Vascular disease is a progressive inflammatory condition fuelled by an unhealthy lifestyle of physical inactivity, cholesterol-rich diet, and smoking. Together with endogenous factors such as age, gender, and autoimmune status, an unhealthy lifestyle fosters a pro-inflammatory and pro-thrombotic milieu, which can lead to endothelial dysfunction, atherosclerotic plaque formation and vascular obstruction or degradation of the subendothelial matrix. Platelet-leukocyte interplay represents an important feature in this context. Platelets get activated in a pro-inflammatory and pro-thrombotic microenvironment and readily interact with innate and adaptive immune cells alike. Even though platelet affinity for physical cell-cell contact is highest with monocytes/macrophages and neutrophils, platelets also avidly interact with lymphocytes by soluble mediators. Platelet-leukocyte crosstalk regulates essential immune responses, supporting leukocyte recruitment at sites of vascular insult, promoting proliferation and differentiation of leukocytes and enhancing pro-inflammatory effector functions such as cytokine and reactive oxygen production. However, under certain conditions platelet-leukocyte interplay also dampens the inflammatory process. Crosstalk of platelet and leukocytes thus represents a driving force in vascular disease. In this review, we highlight the impact of various risk factors for vascular disease on platelet-leukocyte interactions and discuss the underlying mechanisms of platelet-mediated changes in immune responses and the effect of immune cells on the haemostatic system. As the underlying pathologies differ between vascular diseases, we summarize our current knowledge on platelet-leukocyte interplay in chronic vascular diseases such as abdominal aortic aneurysm, peripheral and coronary artery disease as well as acute vascular diseases such as ischaemic stroke and venous thromboembolism.

Citing Articles

Association between mean platelet volume and adiponectin in patients with metabolic syndrome.

Marinkovic M, Nesic J, Petrovic I, Jovanovic I, Sekulic M, Djukic S J Appl Biomed. 2025; 22(4):208-213.

PMID: 40033808 DOI: 10.32725/jab.2024.022.


Platelets Modulate Leukocyte Population Composition Within Perivascular Adipose Tissue.

Corken A, Weinkopff T, Wahl E, Sikes J, Thakali K Int J Mol Sci. 2025; 26(4).

PMID: 40004089 PMC: 11855773. DOI: 10.3390/ijms26041625.


Colchicine for the primary prevention of cardiovascular events.

Marti-Carvajal A, Gemmato-Valecillos M, Monge Martin D, De Sanctis J, Marti-Amarista C, Hidalgo R Cochrane Database Syst Rev. 2025; 2:CD015003.

PMID: 39927511 PMC: 11808834. DOI: 10.1002/14651858.CD015003.pub2.


Platelet signaling in immune landscape: comprehensive mechanism and clinical therapy.

Yan M, Wang Z, Qiu Z, Cui Y, Xiang Q Biomark Res. 2024; 12(1):164.

PMID: 39736771 PMC: 11686937. DOI: 10.1186/s40364-024-00700-y.


Platelet-Leukocyte Aggregate and Interleukin-6: An Emerging Perspective on a New Diagnostic and Therapeutic Clue for Acute Coronary Syndrome, A Case-Control Study.

Ghorbani M, Bashash D, Gheydari M, Mohammadi M, Shahraki H, Yazdanparast S Health Sci Rep. 2024; 7(12):e70209.

PMID: 39669190 PMC: 11635124. DOI: 10.1002/hsr2.70209.